Holen Sie sich die Stockscreener-App
4.70
4.21%
0.19
Handel nachbörslich:
4.70
Schlusskurs vom Vortag:
$4.51
Offen:
$4.6
24-Stunden-Volumen:
268.18K
Relative Volume:
0.91
Marktkapitalisierung:
$236.38M
Einnahmen:
$100.39M
Nettoeinkommen (Verlust:
$-217.57M
KGV:
-1.138
EPS:
-4.13
Netto-Cashflow:
$-180.72M
1W Leistung:
-2.29%
1M Leistung:
-2.29%
6M Leistung:
-1.26%
1J Leistung:
+88.00%
1-Tages-Spanne:
$4.47
$4.80
1-Wochen-Bereich:
$4.34
$4.80
52-Wochen-Spanne:
$1.535
$6.40
2 Seventy Bio Inc Stock (TSVT) Company Profile
Firmenname
2 Seventy Bio Inc
Sektor
Branche
Telefon
339-499-9300
Adresse
60 BINNEY STREET, CAMBRIDGE
2 Seventy Bio Inc Stock (TSVT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-09-13 | Herabstufung | Goldman | Buy → Neutral |
| 2023-09-12 | Herabstufung | Guggenheim | Buy → Neutral |
| 2023-07-28 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2022-10-31 | Eingeleitet | Guggenheim | Buy |
| 2022-05-02 | Eingeleitet | Goldman | Buy |
| 2022-02-10 | Eingeleitet | SVB Leerink | Outperform |
| 2022-01-06 | Eingeleitet | Cowen | Outperform |
| 2021-11-09 | Eingeleitet | Canaccord Genuity | Buy |
| 2021-11-08 | Eingeleitet | Morgan Stanley | Overweight |
| 2021-11-08 | Eingeleitet | Wedbush | Outperform |
Alle ansehen
2 Seventy Bio Inc Aktie (TSVT) Neueste Nachrichten
Layoff Tracker: Compass Pathways to Lay Off 30% of Employees - BioSpace
2seventy bio, Inc. (NASDAQ:TSVT) Shares Sold by Exchange Traded Concepts LLC - Defense World
BioAegis Therapeutics Enrolls First Patient in Phase 2 Clinical Trial of Gelsolin, an Immune Regulator, for the Treatment of Acute Respiratory Distress Syndrome (ARDS) - Yahoo Finance
Dimensional Fund Advisors LP Sells 24,371 Shares of 2seventy bio, Inc. (NASDAQ:TSVT) - Defense World
TSVT INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into 2seventy bio, Inc. and Encourages Investors to Contact the Firm - GlobeNewswire Inc.
2seventy bio Provides Update on KarMMa-9 Study and Previews Anticipated Strong Third Quarter Revenue Performance - Business Wire
Seven Eight Capital LP Makes New $197,000 Investment in Beyond, Inc. (NYSE:BYON) - Defense World
Q&A: Athens legends Five Eight and the makers of their new documentary film, "Weirdo" - Online Athens
Four killed, dozens injured in Alabama mass shooting - Daily Sun
Seven Eight Capital LP Sells 536 Shares of Dell Technologies Inc. (NYSE:DELL) - Defense World
Four dead, 17 others shot in Birmingham mass shooting - WJLA
Five Below, Inc. (NASDAQ:FIVE) Stake Raised by Teca Partners LP - Defense World
Four killed, over 20 injured in Birmingham, Alabama shooting - Thaiger World
At least four dead and dozens injured in shootout with multiple assailants in the United States - Top Buzz Times
Four people dead and dozens injured in US mass shooting horror - Express
Analyst bullish on Tectonic's TX45 ahead of full trial results presentation at AHA - Investing.com India
Tectonic Therapeutic Announces Favorable Phase 1a Safety, Tolerability and PK/PD Results for Lead Program TX45 - GlobeNewswire
Hedge fund Two Sigma in settlement talks with US SEC, WSJ reports - XM
US data: key federal and state updates (13 – 19 Sep) - Lexology
The LYCRA Company Presents Seminars on Sustainable Elastane Solutions at the 63rd Dornbirn Global Fiber Congress - Via Ritzau
Jessica Snow Sells 7,816 Shares of 2seventy bio, Inc. (NASDAQ:TSVT) Stock - Defense World
2seventy bio, Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year - Yahoo Finance
2seventy bio Reports Second Quarter Financial Results and Recent Operational Progress - Business Wire
2seventy bio to Report Second Quarter 2024 Financial Results on August 7, 2024 - Business Wire
Biopharma Layoff Tracker 2024: Cue, Anokion, GlycoMimetics and More Cut Staff - BioSpace
Annovis Bio Inc (ANVS-N) QuotePress Release - The Globe and Mail
Royals select Florida 2-way star Caglianone 6th overall - theScore
Biopharma Layoff Tracker 2024: Spark, Novartis, Indivior and More Cut Staff - BioSpace
Finanzdaten der 2 Seventy Bio Inc-Aktie (TSVT)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.02%
0.47%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Kapitalisierung:
|
Volumen (24h):